



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911



MEMORANDUM OF UNDERSTANDING

BETWEEN

INDIAAI – DIGITAL INDIA

CORPORATION

AND

INDIAN COUNCIL OF MEDICAL

RESEARCH

This Memorandum of Understanding (“**MoU**”) is entered into on the 7th day of May, 2026 (“**Effective Date**”)

BY AND BETWEEN

IndiaAI, established as an independent business division under the Digital India Corporation by the Ministry of Electronics and Information Technology (MeitY), Government of India, having its office at Electronics Niketan, 6, CGO Complex, Lodhi Road, New Delhi – 110003 (hereinafter referred to as “**IndiaAI**”, which expression shall, unless repugnant to the context, include its successors and permitted assigns);

AND

Indian Council of Medical Research (**ICMR**), India’s apex body for planning, coordinating and promoting biomedical and health research, having its office at V. Ramalingaswami Bhavan, Ansari Nagar, New Delhi – 110029 (hereinafter referred to as “**ICMR**”, which expression shall, unless repugnant to the context, include its successors and permitted assigns).

IndiaAI and ICMR are hereinafter individually referred to as a “Party” and collectively as the “Parties”.

RECITALS

Whereas IndiaAI is the implementation agency for the IndiaAI Mission, a strategic initiative of the Government of India to foster a robust, inclusive and responsible Artificial Intelligence ecosystem through its key pillars including IndiaAI Compute Capacity, IndiaAI Innovation Centre, IndiaAI Application Development Initiative, IndiaAI Startup Financing, IndiaAI FutureSkills, IndiaAI Dataset Platform (AIKosh), and Safe & Trusted AI.

Whereas ICMR conducts and supports extramural and intramural biomedical and health research across India and generates datasets of national importance that may support AI-driven innovation in healthcare.

Whereas ICMR, in collaboration with the Indian Institute of Science (IISc) and ARTPARK (AI & Robotics Technology Park), has developed the MIDAS (Medical Imaging Datasets for India) framework, designed to create high-quality, standardised, AI-ready biomedical datasets representative of India's diversity.

Whereas ICMR intends to expand the MIDAS framework through a hub-and-spoke model by identifying and developing regional thematic nodal centres across India for the development of high-quality, standardised, AI-ready biomedical datasets representative of the country's demographic and geographic diversity.

Whereas the Parties share a common objective to accelerate AI-enabled innovation in healthcare in alignment with national priorities and applicable laws and legal standards.

Whereas the Parties intend to establish a common framework to facilitate in terms of exchange of information, material, resources, responsibilities to carry out, for the purposes of providing impetus to the India's AI Mission and to execute such other agreements as may be necessary for the Mission's objectives.

Now, therefore, the Parties agree as follows:

1. PURPOSE

This MoU establishes a framework for collaboration between the Parties across relevant pillars of the IndiaAI Mission, particularly in relation to:

- 1.1 Onboarding of eligible health research datasets to AIKosh;
- 1.2 Facilitation of access to compute infrastructure under the IndiaAI Compute Capacity Pillar; and
- 1.3 Co-development of AI capacity-building programmes and courses in healthcare under the IndiaAI FutureSkills Pillar.

2. AREAS OF COLLABORATION

2.1 AIKosh – Dataset Platform

Alhe

Se

2.1.1. ICMR shall onboard the AIKosh platform to contribute eligible health research artefacts (datasets, metadata, models, toolkits, use cases, etc) and related documentation to the AIKosh platform.

2.1.2. The onboarding, hosting, licensing, access and usage of such artefacts shall be governed by the AIKosh platform's terms of use and privacy policy, as amended from time to time. The provisions of this MoU shall not supersede or modify the said platform's terms and policy.

2.1.3. ICMR shall ensure that artefacts/ datasets shared on AIKosh platform are anonymised or otherwise compliant with applicable laws, institutional ethics approvals, and regulatory requirements.

2.2 Compute Capacity

IndiaAI may facilitate access to GPU and related compute resources under the IndiaAI Compute Capacity Pillar at subsidised rates, subject to availability of resources, applicable policies and guidelines of IndiaAI, necessary internal approvals, and execution of a separate Service Level Agreement (SLA) or Project Agreement.

2.3 AI Courses and Capacity Building

2.3.1. The Parties may jointly co-develop AI courses, training modules and capacity-building initiatives in healthcare under the IndiaAI FutureSkills Pillar.

2.3.2. IndiaAI may support such initiatives through its relevant programmes and platforms, while ICMR shall provide domain expertise and subject-matter inputs.

2.3.3. Any specific course development initiative shall be undertaken pursuant to a separate SLA or Project Agreement, which shall define deliverables,



timelines, financial arrangements (if any), and intellectual property ownership.

2.4 Future Collaboration

The Parties may explore collaboration across other relevant pillars of the IndiaAI Mission (such as IndiaAI Innovation Centre, IndiaAI Application Development Initiative, IndiaAI Startup Financing, and Safe & Trusted AI) subject to mutual agreement and execution of appropriate project-specific agreements.

3. PROJECT-SPECIFIC AGREEMENTS

Any specific project involving compute allocation, joint development of tools, models or applications, course development, research collaboration, or resource commitments, shall be governed by a separate SLA or Project Agreement executed between the Parties. Such agreements shall define scope, roles, financial arrangements, intellectual property, liability, and other operational aspects.

4. FINANCIAL ARRANGEMENTS

4.1 This MoU does not create any financial obligation on either Party. Each Party shall bear its own costs unless otherwise agreed in writing under a separate SLA or Project Agreement.

4.2 Financial commitment, if any, shall be subject to availability of funds and requisite approvals.

5. INTELLECTUAL PROPERTY

5.1 Background Intellectual Property (IP) shall remain the sole property of the originating Party.

5.2 Where intellectual property is created or developed jointly in connection with a project undertaken pursuant to a separate SLA or Project Agreement, as the case may be, all rights, title, and interest, including ownership and usage

Alhe

13

rights therein, shall be determined strictly in accordance with the terms and conditions set forth in such SLA or Project Agreement.

5.3 No license, right or interest in the intellectual property of either Party is granted under this MoU except as expressly agreed in writing.

6. CONFIDENTIALITY

6.1 Confidential Information” means any and all information (whether in oral, written or electronic form) relating to the minutia of research and development proposals, presentations, Intellectual Property stated in the research and development proposals, due diligence reports, in-house analysis reports and Freedom to operate reports, information on business and finances, unpublished data, organizational and individual information, proposed technology or intended inventions/ procedures, nature of research and/or plans for prioritizing research, commercialization strategy, technical validation, budgets and strategies, minutes of the meeting(s) or other agnate materials including any notes or summaries derived from those materials of the Disclosing Party.

6.2 Neither Party shall use or share the Confidential Information of the other Party, except to the extent agreed and needed in the exercise of rights and to fulfil obligations, if any, under this MoU.

6.3 Each Party shall protect the Confidential Information of the other Party with the same degree of care as accorded to its own Confidential Information and undertakes not to disclose the same to any third party except when obligated by law, regulation, court order after giving reasonable notice to the Disclosing Party.

6.4 This confidentiality obligation shall not apply to information which is generally known to third parties, or which can be shown to have been produced by a third party which is independent of either Party, or which has

Alhe

13

been acquired from a third party without breach of the nondisclosure obligation of the Parties, or to the extent a Party is required by statutory law or regulations to reveal any of the information it has obtained.

6.5 This clause shall survive termination of the MoU.

7. PUBLICITY

Neither Party will: (i) use the other Party's name or logo, nor (ii) make a public statement, announcement or issue a press release or any other form of communication about the fact that this MOU has been entered into or as to its content without the written approval and consent of the other Party.

8. NATURE OF THE MOU

Except for Clauses 5 (Intellectual Property), 6 (Confidentiality), 9 (Indemnity), and 12 (Governing Law and Dispute Resolution), this MoU is non-binding and reflects the intent of the Parties to collaborate on a best-efforts basis.

9. INDEMNITY

9.1 Each Party shall be responsible for its own acts and omissions. Any specific indemnity obligations, if applicable, shall be set forth in the relevant project-specific SLAs.

9.2 Users accessing artefacts including datasets through AIKosh platform shall be governed by the applicable platform terms and policy.

10. TERM AND TERMINATION

10.1 This MoU shall remain in force for a term of three (03) years from the Effective Date with automatic renewal unless terminated by either Party by providing ninety (90) days' prior written notice.

10.2 Termination shall not affect obligations expressly stated to survive termination.

Alha

13

11. NON-EXCLUSIVITY

This MoU is non-exclusive. Each Party may enter into similar arrangements with other entities.

12. GOVERNING LAW AND DISPUTE RESOLUTION

12.1 This MoU shall be governed by the laws of India, as amended from time to time.

12.2 Any dispute arising under this MoU shall first be resolved amicably between the Parties. Failing amicable resolution, the matter may be escalated to the Secretary, Department of Health Research, and the Secretary, MeitY, whose joint decision shall be final.

13. AMENDMENT

Any amendment or modification to any part of this MoU shall be effective only in writing signed by and behalf of authorised representatives of both Parties.

14. NOTICE







All notices shall be in writing and sent to the respective authorised representatives at their official addresses. Any notice provided pursuant to this clause shall be deemed effective upon receipt by the Party to whom it was addressed if delivered via following methods: (a) in case of notice being delivered in person, when delivered and acknowledged by the recipient as such; (b) if delivered through speed-post or certified mail (return receipt requested), the third clear day after the date of posting; (c) if sent by electronic mail, forty-eight (48) hours after the electronic mail is sent.

Alhe

13

IN WITNESS WHEREOF

The Parties hereto have executed this MoU on the Effective Date written above.

For ICMR	For IndiaAI
<p>Signature:</p>  <p>Name: Dr. Alka Sharma Addl. DG, (Extramural Research) ICMR Date: 07-05-2026</p>	<p>Signature:</p>  <p>Name: Ms. Kavita Bhatia COO, IndiaAI Date: 07-05-2026</p>
<p>Signature:</p>  <p>(Witness From ICMR) Name: Prof Harpreet Singh Scientist-G, ICMR Date: 07-05-2026</p>	<p>Signature:</p>  <p>(Witness From IndiaAI) Name: Mr. Natla Sudheer Reddy Scientist-C, MeitY Date: 07-05-2026</p>
<p>Signature:</p>  <p>(Witness From ICMR) Name: DR. TARUNA MADAN GUPTA Designation: SCI 'G' DIV, DEV. RES. Date: 07-05-2026</p>	<p>Signature:</p>  <p>(Witness From IndiaAI) Name: Swamee Singh Designation: Gm- Data Science Date: 07-05-2026</p>